FC2ブログ

バイオの戯言

ライフサイエンスに関する話題についてコメント(戯言?)を述べていくブログです。

スポンサーサイト 

上記の広告は1ヶ月以上更新のないブログに表示されています。
新しい記事を書く事で広告が消せます。
[ --/--/-- --:-- ] スポンサー広告 | トラックバック(-) | コメント(-)

【プレスリリースメモ】 RNAi関係 (2013.3.30)  

<Alnylam Pharmaceuticals>
Alnylam Initiates Phase I Clinical Study for ALN-TTRsc, a Subcutaneously Administered RNAi Therapeutic Targeting Transthyretin (TTR) for the Treatment of TTR-Mediated Amyloidosis (ATTR)(2013.3.18)

<Antisense Therapeutics>
ATL1102 Development and Agreement Update(2013.3.18)
ATL1103 Phase I Trial Data to be presented at Acromegaly Conference(2013.3.21)
Change of Directors Interest Notice (MD)(2013.3.25)

<Arrowhead Research>
Arrowhead Induces 90% Reduction in Hepatitis B Antigens in Chimpanzee with Chronic Infection: Data Follow Previous Report of Reduction in Viral DNA(2013.3.25)

<Asuragen>
Study Finds New Genetic Test Better Predicts Mother’s Risk of Having a Child With Fragile X Syndrome(2013.3.2)

<Ceregene>
Ceregene and Alzheimer's Disease Cooperative Study Group Complete Enrollment of CERE-110 Phase 2 Trial(2013.3.13)

<Cerulean Pharma>
Cerulean Announces Results from Phase 2b Lung Cancer Trial(2013.3.22)

<CureVac GmbH>
CureVac Initiates Phase 2b Clinical Trial of its mRNA-Based Cancer Vaccine in Patients with Castration-Resistant Prostate Cancer(2013.3.27)

<Dicerna Pharmaceuticals>
Dicerna Announces Patent Issuance for DsiRNAs Directed at the KRAS Gene, a Key Cancer Regulator(2013.3.19)

<DNA THERAPEUTICS>
DNA Therapeutics was awarded as the most innovative biotech for Biovision Investor Conference 2013(2013.3.26)

<Dynavax Technologies>
Dynavax Appoints David Novack as Senior Vice President, Operations and Quality(2013.3.21)

<Enzon Pharmaceuticals>
Enzon Reports Fourth Quarter and Full Year 2012 Results(2013.3.19)

<Exiqon A/S>
Exiqon A/S - Exiqon launches LNA™ gapmers for inhibition of mRNA and lncRNA in functional studies(2013.3.19)

<Galena Biopharma>
Galena Biopharma Acquires Abstral(R) (fentanyl) Sublingual Tablets in U.S., a Novel, Best-in-Class Treatment Approved for Breakthrough Cancer Pain(2013.3.18)
Galena Biopharma to Present at the 20th Annual Future Leaders in the Biotech Industry Conference(2013.3.29)

<InteRNA Technologies B.V.>
InteRNA Technologies secures additional equity financing to progress lead program for melanoma treatment(2013.3.26)

<Isis Pharmaceuticals>
Data From ISIS-SMN Rx Phase 1 Study in Children With Spinal Muscular Atrophy Presented at the American Academy of Neurology Meeting(2013.3.20)
Isis Provides Update on CHMP Opinion on KYNAMRO™ (mipomersen)(2013.3.22)

<Mirus Bio>
TransIT-BrCa Transfection Reagent from Mirus Bio(2013.3.22)

<OncoGenex Technologies>
OncoGenex Pharmaceuticals to Present at Upcoming Investor Conference(2013.3.28)

<Pharmaxis>
Pharmaxis Receives Complete Response Letter from FDA on Bronchitol(2013.3.19)

<Regulus Therapeutics>
Regulus to Present at Future Leaders in the Biotech Industry Conference(2013.3.28)

<Rosetta Genomics>
Rosetta Genomics Receives 25th U.S. Patent Allowance(2013.3.18)
Rosetta Genomics To Host Business Update Conference Call on April 10, 2013(2013.3.25)

<RXi Pharmaceuticals>
RXi Pharmaceuticals Reports Full Year 2012 Financial Results(2013.3.29)

<Santaris Pharma>
Research Published in the New England Journal of Medicine Demonstrates Marked and Long-Lasting Antiviral Activity Against HCV for Santaris Pharma A/S’ Miravirsen, the First MicroRNA-Targeted Drug to Enter Clinical Trials(2013.3.27)

<Tekmira Pharmaceuticals>
Tekmira Conference Call and Webcast Advisory: Corporate Update and Year-End 2012 Financial Results(2013.3.20)
Tekmira Provides Corporate Update and Announces Year-End Audited 2012 Results(2013.3.27)

<Valeant Pharmaceuticals>
Valeant Pharmaceuticals International, Inc. Agrees to Acquire Obagi Medical Products, Inc. for $19.75 Per Share in Cash(2013.3.20)
Valeant Pharmaceuticals Announces Private Exchange Offer(2013.3.29)

<アンジェスMG>
CIN 治療ワクチンの探索的臨床試験(ステップ2)の結果について(2013.3.18)
【トピックス】日本証券新聞に弊社記事が掲載されました。(2013.3.25)
日本臓器製薬とアンジェスMGがNF-κB デコイオリゴを用いた椎間板性腰痛症治療薬の日本における独占的開発販売契約を締結(2013.3.26)
IR情報/IRライブラリー:株主総会招集通知等を更新しました(2013.3.28)

<ステリック再生医科学研究所>
NASH-肝癌モデル(STAM®モデル)マウスに関する当社論文 “A murine model for non-alcoholic steatohepatitis showing evidence of association between diabetes and hepatocellular carcinoma.” がMedical Molecular Morphologyに掲載(2013.2.22)

<リボミック>
3月19日付にて取締役に石川廣が就任致しました。(2013.3.19)


スポンサーサイト
[ 2013/03/30 10:49 ] プレスリリース | TB(0) | CM(0)
コメントの投稿













管理者にだけ表示を許可する
最新ニュース
お気に入り
カレンダー(月別)
09 ≪│2018/10│≫ 11
- 1 2 3 4 5 6
7 8 9 10 11 12 13
14 15 16 17 18 19 20
21 22 23 24 25 26 27
28 29 30 31 - - -
特選品
特許関係の書籍-3
特許関係の書籍-2
特許関係の書籍-1
情報関係の書籍
月別アーカイブ
プロフィール

のぐひで

Author:のぐひで
FC2ブログへようこそ!



上記広告は1ヶ月以上更新のないブログに表示されています。新しい記事を書くことで広告を消せます。